Tag:
AstraZeneca
Latest Headlines
Latest Headlines
Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca
Bristol-Myers Squibb is the leader right now in immuno-oncology and checkpoint inhibitors and it clearly is willing to get aggressive about defending that early edge. In a move that shows just how competitive this blockbuster field has become, the big biotech wants to force one of its ex-R&D leaders in I/O to sit out the next year rather than go to work for a major league rival.
Doctors look for a single test to identify best immunotherapy drugs for cancer patients
With a new crop of cancer immunotherapy drugs that offer the hope of battling forms of cancer previously thought untreatable, researchers and physicians are looking for tests that can better pinpoint which patients respond to each of the treatments.
AstraZeneca's Definiens rolls out biomarker data service
Definiens introduced a suite of services to help companies gather data from tissue samples and use the resource to identify potential companion diagnostics.
AZ in distribution pact with Dr. Reddy's to extend reach in India
AstraZeneca Pharma India has signed up Dr. Reddy's Laboratories to distribute its diabetes medicines Riax and Riax-M in India as domestic and foreign companies look for advantages in a crucial and sharply competitive market where generic activity is on the rise.
UPDATED: Clovis boasts promising ovarian cancer data as lung cancer results fade
Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new--though less impressive--data to back up its lead drug for non-small cell lung cancer.
AstraZeneca adds Lilly to its stable of immuno-oncology collaborators
AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.
Happy anniversary? Taking stock at Pfizer, AstraZeneca one year after the mega-mega-deal collapse
One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.
AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik
When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).
Can AZ salvage brodalumab against next-gen psoriasis field?
The crowded next-gen psoriasis landscape may lose a contender, now that Amgen has bailed out of its brodalumab pact with AstraZeneca. And if the British pharma decides to go it alone, it'll face plenty of contenders--not to mention reports of side effects--that could make building market share an uphill battle.
UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a shoo-in at the FDA. But late Friday evening, Amgen abruptly said it was pulling out of the long-running collaboration on the high-profile IL-17 program after evaluating the likely commercial impact it would face in light of the suicidal thoughts some patients reported during the studies.
